The final, formatted version of the article will be published soon.
REVIEW article
Front. Pharmacol.
Sec. Translational Pharmacology
Volume 15 - 2024 |
doi: 10.3389/fphar.2024.1519479
Applications of Polymeric Nanoparticles in Drug Delivery for Glioblastoma
Provisionally accepted- First Affiliated Hospital of Jilin University, Changchun, China
Glioblastoma (GBM) remains one of the most aggressive and treatment-resistant brain tumors, necessitating innovative therapeutic approaches. Polymer-based nanotechnology has emerged as a promising solution, offering precise drug delivery, enhanced blood-brain barrier (BBB) penetration, and adaptability to the tumor microenvironment (TME). This review explores the diverse applications of polymeric nanoparticles (NPs) in GBM treatment, including delivery of chemotherapeutics, targeted therapeutics, immunotherapeutics, and other agents for radiosensitization and photodynamic therapy. Recent advances in targeted delivery and multifunctional polymer highlight their potential to overcome the challenges that GBM brought, such as heterogeneity of the tumor, BBB limitation, immunosuppressive TME, and consideration of biocompatibility and safety. Meanwhile, the future directions to address these challenges are also proposed. By addressing these obstacles, polymer-based nanotechnology represents a transformative strategy for improving GBM treatment outcomes, paving the way for more effective and patient-specific therapies.
Keywords: Glioblastoma, Nanoparticles, polymer, Drug delivery, Treatment
Received: 30 Oct 2024; Accepted: 22 Nov 2024.
Copyright: © 2024 Tan, Liu, Wang, Yu and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Bin Tan, First Affiliated Hospital of Jilin University, Changchun, China
Shuhan Liu, First Affiliated Hospital of Jilin University, Changchun, China
Feng Wang, First Affiliated Hospital of Jilin University, Changchun, China
Ying Yu, First Affiliated Hospital of Jilin University, Changchun, China
Tianmeng Sun, First Affiliated Hospital of Jilin University, Changchun, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.